Protocol: Personality assessment as a support for referral and case-work in treatment for substance use disorders (PASRC-study) by Hesse, Morten & Pedersen, Mads K
BioMed  Central
Page 1 of 9
(page number not for citation purposes)
BMC Psychiatry
Open Access Study protocol
Protocol: Personality assessment as a support for referral and 
case-work in treatment for substance use disorders (PASRC-study)
Morten Hesse* and Mads K Pedersen
Address: University of Aarhus, Centre for Alcohol and Drug Research, Købmagergade 26E, 1150 Copenhagen C, Denmark
Email: Morten Hesse* - mh@crf.au.dk; Mads K Pedersen - mkp@crf.au.dk
* Corresponding author    
Abstract
Background: Assessment of co-morbid personality disorders in substance use disorders may lead
to important insights concerning individual patients. However, little is known about the potential
value of routine personality disorder assessment in a clinical context.
Methods:  Patients are adults with past-year substance dependence seeking treatment at a
centralized intake unit for substance abusers in the City of Copenhagen. A randomized controlled
trial of assessment of personality disorders and individual feedback vs. a general life situation
interview. Patients are followed at 3 and 6 months post-treatment
Discussion: If routine personality assessment improves outcomes of substance abuse treatment,
the clinical implication is to increase the use of personality disorder assessment in substance abuse
treatment settings.
Trial registration: Current controlled trials ISRCTN39851689
Background
Substance use disorders and personality disorders often
co-occur [1,2]. Patients with personality disorders are
commonly seen in treatment programs for substance
abuse, consume a disproportionate amount of staff time,
and are more likely to drop out from substance abuse
treatment interventions [3,4].
At the same time, therapists and other professionals tend
to react negatively to patients with personality disorders at
an emotional level [5], this is especially the case with clus-
ter B (dramatic/erratic) personality disorders [6].
Even if patients with personality disorders benefit from
treatment, they often remain more symptomatic than
patients without personality disorders, and remain at a
lower level of functioning [7,8].
Therefore, treatment that meets the needs of patients with
substance abuse and personality disorders is needed.
Recently, some studies have shown that integrated treat-
ment for personality disorders and substance abuse may
be superior to treatment that focuses solely on substance
abuse treatment [9-11].
This randomized experimental study is designed to assess
whether systematic assessment of personality disorders
improves outcomes, vs. assessment of Axis I disorders
alone.
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The objective of this study is to estimate the effect of rou-
tine assessment of co-morbid axis II disorders in a central-
ized intake unit for substance use disorders.
Method
Design
The study is a randomized experimental trial comparing
assessment of Axis I disorders alone with assessment of
both Axis I disorders and Axis II disorders. For both treat-
ment conditions, patients are given feedback about the
results of assessment and offered the opportunity to have
their key-worker receive the same feedback.
Participants/setting
Participants are adults seeking treatment for a substance
use related disorder at the Central Intake Unit (CIU) in
Copenhagen, Denmark (Købmagergade 26E, St., 1150
Copenhagen C).
Referral and recruitment
Patients are recruited by caseworkers. The management of
the intake unit and the management of the centre have
instructed all caseworkers to ask all new referrals or those
referred for a change in treatment to participate in the
study.
Caseworkers inform patients that the study concerns
assessment of psychological problems, behaviour and
other disorders, and that patients will be randomly
assigned to one of two types of interviews. The primary
interviewer later gives detailed information about the
study procedure.
Inclusion criteria
To be eligible for the study, patients must satisfy the fol-
lowing criteria:
• Be at least 18 years of age.
• Not currently be psychotic or have a known diagnosis of
schizophrenia excluding patients from treatment at the
intake unit.
• Not currently be involved in an ongoing treatment for a
drug or alcohol problem. Patients who are currently
involved in treatment for alcohol or drug abuse will, how-
ever, not be referred to the CIU.
• Have past-year substance dependence, as indicated by a
score on the SDS of 3 or more for either alcohol or drugs.
• Speak Danish or English fluently.
• Give informed consent.
The assessment and feedback takes place in the first three
weeks of treatment.
Table 1 gives an overview of the interviews and question-
naires conducted at the different assessment times. Figure
1 represents the research procedure schematically. Figure
2 contains the expected participant flow.
Outcome criteria
The main outcome criterion will be the following:
Improvement in at least one of the following areas,
described as a 30% decline in score, with no concurrent
deterioration in any area: global functioning, as measured
by the Work and Social Adjustment Scale [12]; psychiatric
symptoms, as measured by the Kessler 6+ [13,14]; sub-
stance use, as measured by the Opiate Treatment Index
drug use indicator [15]; treatment engagement, as meas-
ured by treatment staff, using the treatment engagement
scale from DATOS [16].
Secondary outcome criteria will be
• Retention in treatment, defined as being retained in the
same treatment that patients were first referred to after
their contact with the intake unit at 3 and 6 months fol-
low-up, or having completed that treatment as planned.
• Understanding of one's own personality and the impact
that personality has on others, as rated by an independent
interviewer [17].
• Readiness to change dysfunctional behaviour, work with
emotional problems, change illicit drug use, and change
alcohol use, as measured by brief 4-item questions,
adapted from the smoking cessation literature [18].
Outcome criteria will be assessed at 3 and 6 months fol-
low-up.
Intake procedure
At intake to the CIU, patients undergo a routine intake
interview with a key-worker that includes the Addiction
Severity Index [19]. After the completion of the intake
interview, patients are informed by the caseworker of the
fact that a study of psychopathology is ongoing at the
unit. If the patient agrees to receive further information, a
researcher is contacted, which immediately comes to the
office of the key-worker to meet the patient and schedules
an intake interview.
Baseline interview
At the baseline interview, the interviewer informs the
patient of the study, and explains that the study focuses of
psychological and behavioural problems that people with
substance abuse regularly encounter. He then explainsBMC Psychiatry 2008, 8:30 http://www.biomedcentral.com/1471-244X/8/30
Page 3 of 9
(page number not for citation purposes)
that there are two different interviews, and that patients
will be randomly assigned to one of two types. If asked, he
will explain that he does not yet know what kind of inter-
view he will conduct the second time they meet, but he
will give a further explanation at their second appoint-
ment. If the patient gives consent to participate in the
study, a brief structured assessment of axis I disorders is
conducted. The assessment is kept brief, in order to reduce
assessment reactivity, i.e., the effects that assessment can
have on treatment outcomes [20].
The instruments used are therefore chosen to be brief, but
have strong indications of validity:
Flowchart of the process from information to follow-up Figure 1
Flowchart of the process from information to follow-up.
  Information after intake interview 
at central intake unit 
Week 1. Intake screening and axis 
I assessment. Introduction to 
follow-up interviewer 
Randomization 
Exclusion: Does not 
satisfy criteria for 
substance dependence 
Personality disorder assessment  Client-driven interview 
Individual feedback about axis I 
and II disorders 
Individual feedback about axis I 
disorders 
Feedback with patient and caseworker if patient agrees 
Month 3: First follow-up assessment 
Month 6: Second follow-up assessment BMC Psychiatry 2008, 8:30 http://www.biomedcentral.com/1471-244X/8/30
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Flowchart of participants Figure 2
Flowchart of participants.
 
  Approached: (n= ) 
 
Intake screening and axis I 
assessment. Introduction to 
follow-up interviewer 
Randomization 
Exclusion: Does not 
satisfy criteria for 
substance dependence (n= 
) 
Allocated to personality 
disorder assessment (n= ) 
Did not show up for second 
interview (n= ) 
Did not complete feedback 
(n= ) 
Refused feedback to 
caseworker (n= ) 
Refused: (n= ) 
Accepted, but contact not 
established: (n= ) 
Allocated to personality 
client-driven interview (n= ) 
Did not show up for second 
interview (n= )  Allocation
Did not complete feedback 
(n= ) 
Refused feedback to 
caseworker (n= ) 
Lost to follow-up (n= ) 
For reason 
Lost to follow-up (n= )  Follow-up
For reason 
Analyzed (n= )  Analyzed (n= )  Analysis  Lost to follow-up (n= )  Lost to follow-up (n= ) 
For reason  For reason 
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• Anxiety/depression is assessed with The Kessler 6 inter-
view [14].
• Attention Deficit/Hyperactivity Disorder is assessed with
the Adult ADHD Self-Report Scale [14].
• Illicit substance dependence and alcohol dependence
are both assessed by means of the Opiate Treatment Index
substance use items [15].
• Severity of alcohol and illicit drug dependence will be
assessed by the Severity of Dependence Scale [SDS] [21].
• Personality disorder severity is assessed with the Struc-
tured Assessment of Personality – Abbreviated Scale
[SAPAS] [22,23].
If the patient does not speak Danish or English well, does
not screen positive for substance dependence as indicated
by an SDS score of 3 or more for either alcohol or drugs,
a feedback session is scheduled, and the patient is
informed that based on his data, we wish to give him indi-
vidual feedback on the next session.
If the patient satisfies inclusion criteria (speaks Danish or
English; SDS > 3; gives informed consent), a second inter-
view is scheduled. The interviewer will also schedule a
meeting with the researcher conducting follow-up inter-
views.
The patient is then randomized to either experimental or
control conditions.
Second interview – experimental condition
If the patient is randomized to the experimental condi-
tion, the second interview will be an assessment of axis II
disorders. The patient will first receive a brief description
of what personality disorders is, and be given a brief
description of personality disorders as inflexible, mala-
daptive patterns of behaviour that cause significant prob-
lems or distress for themselves or others.
The interview will consist of the following elements:
• The Alcohol Use Disorder and Associated Disorders
Interview Schedule (AUDADIS) section for avoidant,
dependent, obsessive-compulsive, paranoid, schizoid and
histrionic personality disorder [24]. Added items taken
from the Parker Personality inventory will be taken in to
reflect schizotypal personality disorder and narcissistic
personality disorder [25].
• The NPI-16 will be added as a measure of narcissism
[26].
• The Psychiatric Research Interview for Substance and
Mental Disorders (PRISM) [27,28] will be used to assess
borderline and antisocial personality disorder.
Following this, patients will be asked if they have any
questions, and thereafter the interviewer will proceed with
the interview. The interview will contain the following
elements.
The interviewer will be trained through role-plays in
administering the interview package. For the PRISM,
taped interviews will be co-rated to assess the inter-rater
reliability of coding.
Second interview: control condition
The control condition will contain an interview of up to
one hour, where the patient chooses focus based on a list
of items (substance use problems; family; friends; work/
education; etc). The interview is client-driven and follows
an ethnographic approach.
These interviews are taped and used as the basis for a con-
densed summary in the feedback
Randomization and blinding
Randomization will be conducted by means of a prede-
fined list of random numbers, stratified by predefined
characteristics, which will not be disclosed at this point to
reduce risk of breaking of blind. Randomization is exe-
cuted according to a list, the allocation sequence of which
was computer-generated by one of the researchers (MH).
The interviewer will be blinded to randomization at the
baseline interview.
Table 1: Instruments at different assessment moments
Baseline Follow-up Follow-up
Interview:
SAPAS [22, 23] * * *
ASRS [14] * * *
K6 [32] * * *
OTI [15] * * *
SDS – alcohol [21] * * *
SDS – drugs [21] * * *
WAI [29] *




CGI-externalizing [23] * *
CGI-substance use [23] * *
GAF [23] * *
WAI [29] *
Notes: SAPAS: Standardised Assessment of Personality – Abbreviated 
Scale. ASRS: Adult ADHD Self-Report Scale. K6: Kessler 6. OTI: 
Opiate Treatment Index. SDS: Severity of Dependence Scale. WAI: 
Working Alliance Inventory. VAS: Visual analogue scales. CGI: Clinical 
Global Impression. GAF: Global Assessment of Functioning.BMC Psychiatry 2008, 8:30 http://www.biomedcentral.com/1471-244X/8/30
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The follow-up interviewers will be introduced to the
patients at the baseline interview, to assure blinded fol-
low-up assessments.
Withdrawal
A participant can withdraw from the trial at any point,
although information already given to caseworkers can-
not be withdrawn. Participants who withdraw from the
trial treatment will not be asked to attend the follow-up
appointments, and will be deleted from all files.
Feedback and psychoeducation procedure
Patients will receive individual feedback first. The feed-
back is inspired by psychoeducation procedures [17]. For
each diagnosis for which a positive result is found,
patients are first prompted about their knowledge of the
disorder, and then given their test results. Test results will
involve diagnoses and possible treatment options and
implications (e.g., psychotherapy and/or medication for
anxiety/depression; skills training and/or medication for
attention deficit/hyperactivity disorder). For personality
disorders, treatment implications, resources and relevant
treatment options are summarized in Table 2.
Follow-up procedure
Trained interviewers will make contact with study partici-
pants before randomization, but after intake interview.
Interviewers will be blinded to randomization status. The
follow-up interview will contain the same elements as the
baseline interview (i.e., the K6, the ASRS, the WSAS, the
OTI, and the SDS). Also, patients will be asked to rate the
value of the feedback procedure on visual analogue scales
representing the skills of the interviewer (on a line ranging
from "extremely unskilled" to "extremely skilled"), his
knowledge (from very little knowledge, to highly knowl-
edgeable), his degree of interest in the patient, his under-
standing of the patient, the value of the feedback for the
treatment, the value of the treatment for the patient, how
much thought the patient has given the feedback, and
how much work he has done in regard to the issues dis-
cussed in the feedback.
Finally, the patient is asked to rate his alliance with the
caseworker using the Working alliance inventory, patient
version [29].
Table 2: Treatment implications, personal resources, and relevant treatment options for each of the ten personality disorders
Personality 
disorder
Implications Resources Treatment options
Paranoid Problems dealing with high expressed emotion; needs 
time to build trust; needs great patience; problems 
with groups, especially confrontative groups.
Careful, able to cope in 
realistic danger; protects 
own privacy
Counselling; inpatient treatment in small 
wards with great flexibility; not 
exploratory psychotherapy [10]
Schizoid Problems dealing with high expressed emotion; needs 
great patience; does not benefit from requests for 
participation in social activities.
Able to deal with being 
alone;
Counselling; possibly inpatient treatment 
in small wards with great flexibility [10]
Schizotypal Problems dealing with high expressed emotion; needs 




Counselling; possibly inpatient treatment 
in small wards with great flexibility [10]; 
antipsychotic medication
Antisocial Impulse actions; "plays the game"; needs straight talk 
from counsellor or case worker; transgresses 
boundaries in treatment;
Great potential for action 
under many circumstances
Therapeutic community or similar 
treatment [33]; regular addictions 
treatment; cognitive-behavioural 
interventions, or similar
Borderline Impulse actions; transgresses boundaries in treatment; 
needs to learn to cope with emotion; chaotic 
relationships to therapists
Sensitive and able to 
experience emotions
Psychotherapeutic treatment; 
antidepressants; antipsychotics; inpatient 
treatment; long-term involvement
Histrionic Flirts and appears shallow and superficial to others; 
has difficulties focusing on own situation and issues
Charming and outgoing Psychotherapeutic treatment; counselling; 
inpatient treatment; cognitive-behavioural 
interventions
Narcissistic Appears grandiose and arrogant; makes it difficult for 
staff members to intervene ("scares" away all criticism)
Has ability to feel pride Inpatient treatment for drug misuse; self-
change program, cognitive-behavioural 
interventions
Avoidant Difficulty getting out with new people; stays in "safe 
zones", and has difficulty trying out new treatment 
options or seeking social support or employment
Self-protective; sometimes 
able to stay out of trouble by 
keeping away
Psychotherapeutic treatment; 
antidepressants; inpatient or outpatient 
treatment; individual counselling and case 
management








Difficulties concluding in counselling or therapy 
settings; attempts to control counsellor, and other 
professionals
Sticks to goals Psychoeducation;BMC Psychiatry 2008, 8:30 http://www.biomedcentral.com/1471-244X/8/30
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At each interview point, the caseworker is asked to rate the
patient using the clinical global impression scale with
anchor points for alcohol and drug abuse [23], externaliz-
ing behaviour [23], and GAF [23], and to complete the
Working Alliance Inventory, clinician version [29].
Data handling and record keeping
Patient information will only be accessible to the research
team. All data will be link-anonymised so that no patient
identifying information will be kept with raw data. All
files will be kept with the local research teams in a locked
and secure cabinet. Electronic data will be stored on a cen-
tral computer at the research centre.
A personal feedback letter will be given to the patient, in
which the patient appears only with his or her first letter.
If the patient agrees that the information in the personal
feedback should be shared with the caseworker, then the
same letter will be given to the caseworker. Raw data will,
however, only be kept and stored by the Centre for Alco-
hol and Drug Research.
Outcome evaluation
A single measure of outcome will be used as the primary
outcome measure: The proportion of areas in which a
30% reduction occurred at each follow-up wave (K6,
WSAS, and OTI substance use). This measure can theoret-
ically range from -3 (deterioration in all areas) to +3
(improvement in all areas.
The data will be analyzed with mixed effects ordinal
regression, using baseline values of the three outcome
measures as covariates [30].
Risks and anticipated benefits for trial participants and 
society, including how the benefits justify the risks
Patients with substance use disorders and co-morbid per-
sonality disorder experience a number of serious prob-
lems. Patients with co-morbid personality disorder tend
to remain symptomatic long after treatment [7,8], and
patients with some co-morbid personality disorders tend
to commit a substantial amount of the crime that sub-
stance abusers commit [31].
If the findings of this study show that personality assess-
ment can significantly improve the functioning of patients
with substance use disorders, this can have significant
impacts on both the quality of life of patients, and on
society.
The main risk of this study is that patients experience a
worsening of psychiatric symptoms or substance use as a
reaction to receiving a feedback concerning their own per-
sonal functioning. There is some indication that symp-
toms may fail to improve with focus on personality, even
if this focus improves substance use and therapeutic alli-
ance [9]. We will monitor psychiatric symptoms every 3
months during the study, and patients have access to case-
worker, psychiatrist and psychologist at the treatment cen-
tre.
Ethical approval
Institutional Review Boards in Denmark do not approve
or disapprove of trials or other studies of psychosocial
interventions. The medical director of social medicine in
the City of Copenhagen, M.D. Peter Ege, read and
approved the protocol in Danish. Patients will be given
full information about the nature of the study, and be
asked to give informed consent. Patients who refuse par-
ticipation in the study will be given full access to all regu-
lar treatment services in the organisation, similar to the
control group.
Ethically, the issues related to this study concerns the con-
sequences of receiving serious diagnoses for which there is
no clear and simple treatment, in particular personality
disorders. However, although there is no simple treat-
ment, patients are given suggestions and support, and
have access to the support of the treatment centres
When patients in this trial are assessed, they also receive
feedback and advice about how to handle the issues
involved, and their caseworkers are given feedback and
advice on how to best support patients.
Discussion
This paper describes the study protocol of a randomized
controlled trial concerning personality disorder assess-
ment and feedback versus an open interview. The aim of
this study is to assess the potential value of personality
disorder assessment for referral and casework in a real-life
setting. The study design described above has specific
strengths and limitations.
The study has a single-blind design, where patients are
unaware if their treatment is designated as an "experimen-
tal" or "control" treatment. Follow-up interviewers are
blinded to allocation, and we have procedures to reduce
the risk that follow-up interviewers are made aware of
subjects' status (i.e., follow-up interviewers make contact
with patients before randomization is known; patients are
told not to disclose details about the interview to the fol-
low-up interviewers).
The study uses an attention placebo design, which means
that the effects of time and attention are controlled for.
Research has shown strong assessment reactivity in sub-
stance use outcome [20], meaning that patients who are
exposed to assessment show improvement only for that
reason. The amount of contact is controlled for in thisBMC Psychiatry 2008, 8:30 http://www.biomedcentral.com/1471-244X/8/30
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trial. This means that if significant effects are found, they
give strong support to the efficacy of personality disorder
assessment.
The setting in which the study takes place is a community
service. This means that although training and supervi-
sion is provided for caseworkers, the caseworkers are not
primarily working with the research project. While this
may reduce the potential efficacy of the intervention, it
means that the study is in a sense between an efficacy trial
and an effectiveness study.
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